Koers Immunovant, Inc. Nasdaq
Aandelen
US45258J2015
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | 14,41 mln. 13,49 mln. | Marktkapitalisatie | 3,99 mld. 3,74 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -250 mln. -234 mln. | Nettowinst (verlies) 2025 * | -276 mln. -258 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | 653 mln. 611 mln. | Nettoliquiditeiten 2025 * | 532 mln. 498 mln. | EV/omzet 2025 * | 240 x |
K/w-verhouding 2024 * |
-15,4
x | K/w-verhouding 2025 * |
-15,1
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 42,86% |
Recentste transcriptie over Immunovant, Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Peter Salzmann
CEO | Chief Executive Officer | 56 | 01-06-19 |
Eva Barnett
DFI | Director of Finance/CFO | 44 | 04-10-21 |
Sheetal Patel
CTO | Chief Tech/Sci/R&D Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
George Migausky
BRD | Director/Board Member | 69 | 18-12-19 |
Andrew Fromkin
BRD | Director/Board Member | 58 | 18-12-19 |
Douglas Hughes
BRD | Director/Board Member | 62 | 18-12-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+0,40% | 42,86 mld. | |
+11,95% | 42,74 mld. | |
+44,30% | 41,36 mld. | |
-6,20% | 27,68 mld. | |
+5,67% | 25,15 mld. | |
-23,93% | 18,63 mld. | |
+27,59% | 12,37 mld. | |
-3,76% | 11,92 mld. | |
+7,20% | 11,21 mld. |